Phase 3 trial results for Acadia's (NASDAQ:ACAD) drug pimavanserin in treating Parkinson's disease psychosis are in, and the results are very positive. This type of psychosis can affect more than half of all Parkinson's sufferers, and the drug showed statistical significant advantages over a placebo group in reducing hallucinations and delusions. While other anti-psychotics that have been used to treat it off-label, they've been met with only limited success and have sometimes been detrimental to other motor skill treatments for patients, something not found in pimavanserin. The resulting market reaction: Shares of Acadia are up an astounding 140%.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/18/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.